



KAREN L. SMITH, MD, MPH  
Director & State Health Officer

State of California—Health and Human Services Agency  
California Department of Public Health



GAVIN NEWSOM  
Governor

Office of AIDS (OA)  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2019-10

DATE: March 26, 2019

TO: ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF TWO GENERIC ANTIRETROVIRAL (ARV) MEDICATIONS  
AND TWO GENERIC HEPATITIS C VIRUS (HCV) MEDICATIONS TO THE  
ADAP FORMULARY – FOR COPAY COVERAGE

**Effective March 25, 2019**, two generic ARV medications, tenofovir disoproxil fumarate (Viread®) and fosamprenavir (Lexiva®), and two generic HCV medications, sofosbuvir/velpatasvir (Harvoni®) and ledipasvir/sofosbuvir (Epclusa®), have been added to the ADAP formulary. These generics have been added to the ADAP drug formulary for copay coverage only for clients whose healthcare plan requires the use of generics over brand name drugs.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The [ADAP drug formulary](https://cdph.magellanrx.com/member/documents) has been updated to reflect the copay coverage for generic tenofovir disoproxil fumarate, fosamprenavir, sofosbuvir/velpatasvir, and ledipasvir/sofosbuvir. The updated formulary can be accessed at the following URL: (<https://cdph.magellanrx.com/member/documents>).

If you have any questions regarding the addition of these generic medications to the ADAP formulary for copays, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

Sandra Robinson, MBA  
ADAP Branch Chief  
California Department of Public Health